Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study

被引：0

作者：

Horinouchi, H. ^{[1
]}

Nogami, N. ^{[2
]}

Saka, H. ^{[3
]}

Nishio, M. ^{[4
]}

Tokito, T. ^{[5
]}

Takahashi, T. ^{[6
]}

Kasahara, K. ^{[7
]}

Hattori, Y. ^{[8
]}

Ichihara, E. ^{[9
]}

Adachi, N. ^{[10
]}

Sawada, T. ^{[10
]}

Shimamoto, T. ^{[10
]}

Noguchi, K. ^{[10
]}

Pietanza, M. C. ^{[11
]}

Kurata, T. ^{[12
]}

机构：

[1] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[2] Natl Hosp Org Shikoku Canc Ctr, Dept Thorac Oncol, Matsuyama, Ehime, Japan

[3] Natl Hosp Org Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan

[4] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Tokyo, Japan

[5] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka, Japan

[6] Shizuoka Canc Ctr, Div Thorac Oncol Ctr, Nagaizumi, Shizuoka, Japan

[7] Kanazawa Univ Hosp, Dept Resp Med, Kanazawa, Ishikawa, Japan

[8] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan

[9] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan

[10] MSD KK, Tokyo, Japan

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] Kansai Med Univ Hosp, Dept Thorac Oncol, Osaka, Japan

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

151P

引用

页数：2

共 50 条

[1] Health-Related Quality of Life (HRQoL) with Pembrolizumab or Placebo plus Pemetrexed plus Platinum in Patients with Metastatic Non-Squamous NSCLC: Keynote-189
Hui, R.
Garassino, M. C.
Rodriguez-Abreu, D.
Gadgeel, S.
Esteban, E.
Felip, E.
Speranza, G.
Domine, M.
Hochmair, M. J.
Powell, S.
Cheng, S. Y-S
Bischoff, H. G.
Peled, N.
Reck, M.
Garon, E. B.
Boyer, M.
Yang, J.
Burke, T.
Pietanza, M. C.
Gandhi, L.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 47 - 47
[2] Health-Related Quality of Life with Pembrolizumab or Placebo plus Pemetrexed plus Platinum in Non-Squamous NSCLC: KEYNOTE-189
Garassino, M.
Rodriguez-Abreu, D.
Gadgeel, S.
Esteban, E.
Felip, E.
Speranza, G.
Domine, M.
Hochmair, M.
Powell, S.
Cheng, S.
Bischoff, H.
Peled, N.
Reck, M.
Hui, R.
Garon, E.
Boyer, M.
Yang, J.
Burke, T.
Pietanza, M. C.
Gandhi, L.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S155 - S155
[3] Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189
Garon, Edward B.
Aerts, Joachim
Kim, Jong Seok
Muehlenbein, Catherine E.
Peterson, Patrick
Rizzo, Maria Teresa
Gadgeel, Shirish M.
LUNG CANCER, 2021, 155 : 53 - 60
[4] KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC
Gandhi, Leena
Rodgriguez-Abreu, Delvys
Gadgeel, Shirish
Esteban, Emilio
Felip, Enriqueta
De Angelis, Flavia
Domine, Manuel
Clingan, Philip
Hochmair, Maximilian J.
Powell, Steven
Cheng, Susanna Yee-Shan
Bischoff, Helge G.
Peled, Nir
Grossi, Francesco
Jennens, Ross R.
Reck, Martin
Hui, Rina
Garon, Edward B.
Boyer, Michael
Rubio-Viqueira, Belen
Novello, Silvia
Kurata, Takayasu
Gray, Jhanelle E.
Vida, John J.
Wei, Ziwen
Yang, Jing
Raftopoulos, Harry
Pietanza, M. Catherine
Garassino, Marina C.
CANCER RESEARCH, 2018, 78 (13)
[5] Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study
Horinouchi, Hidehito
Nogami, Naoyuki
Saka, Hideo
Nishio, Makoto
Tokito, Takaaki
Takahashi, Toshiaki
Kasahara, Kazuo
Hattori, Yoshihiro
Ichihara, Eiki
Adachi, Noriaki
Noguchi, Kazuo
Souza, Fabricio
Kurata, Takayasu
CANCER SCIENCE, 2021, 112 (08) : 3255 - 3265
[6] KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
Gadgeel, S.
Rodriguez-Abreu, D.
Felip, E.
Esteban, E.
Speranza, G.
Reck, M.
Hui, R.
Boyer, M.
Garon, E. B.
Horinouchi, H.
Cristescu, R.
Aurora-Garg, D.
Lunceford, J.
Kobie, J.
Ayers, M.
Piperdi, B.
Pietanza, M. C.
Garassino, M. C.
ANNALS OF ONCOLOGY, 2019, 30 : 64 - 65
[7] Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Gadgeel, Shirish
Rodriguez-Abreu, Delvys
Speranza, Giovanna
Esteban, Emilio
Felip, Enriqueta
Domine, Manuel
Hui, Rina
Hochmair, Maximilian J.
Clingan, Philip
Powell, Steven F.
Cheng, Susanna Yee-Shan
Bischoff, Helge G.
Peled, Nir
Grossi, Francesco
Jennens, Ross R.
Reck, Martin
Garon, Edward B.
Novello, Silvia
Rubio-Viqueira, Belen
Boyer, Michael
Kurata, Takayasu
Gray, Jhanelle E.
Yang, Jing
Bas, Tuba
Pietanza, M. Catherine
Garassino, Marina C.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (14) : 1505 - +
[8] Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)
Patel, J. D.
Hensing, T. A.
Rademaker, F.
Hart, E.
Obasaju, C. K.
Treat, J.
Milton, D.
Bonomi, P. D.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[9] Pembrolizumab plus pemetrexed and platinum vs placebo plus pemetrexed and platinum as first-line therapy for metastatic nonsquamous NSCLC: analysis of KEYNOTE-189 by STK11 and KEAP1 status
Gadgeel, Shirish M.
Rodriguez-Abreu, Delvys
Felip, Enriqueta
Esteban, Emilio
Speranza, Giovanna
Reck, Martin
Hui, Rina
Boyer, Michael
Garon, Edward B.
Horinouchi, Hidehito
Cristescu, Razvan
Aurora-Garg, Deepti
Loboda, Andrey
Lunceford, Jared
Kobie, Julie
Ayers, Mark
Piperdi, Bilal
Pietanza, M. Catherine
Garassino, Marina C.
CANCER RESEARCH, 2020, 80 (16)
[10] COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE
Chouaid, C.
Bensimon, L.
Millier, A.
Clay, E.
Insinga, R.
Arunachalam, A.
Khandelwal, A.
Bachelot, Levy L.
Levy, P.
VALUE IN HEALTH, 2019, 22 : S458 - S458

← 1 2 3 4 5 →